Bli medlem
Bli medlem

Du är här


Active Biotech: Annual General Meeting of Active Biotech AB

The Annual General Meeting of Active Biotech was held on May 15, 2014.

In accordance with the Board of Directors' proposal, it was resolved that no
dividend would be paid.

The board members and the managing director were discharged from liability
with respect to their management of the company for 2013.

In accordance with the Election Committee's proposal, the Board members Mats
Arnhög, Peter Hofvenstam, Rolf Kiessling, Magnhild Sandberg, Peter Sjöstrand
and Peter Thelin were re-elected. The Meeting also resolved to re-elect Mats
Arnhög as Chairman of the Board. KPMG AB was re-elected as auditors.

Furthermore, in accordance with the Election Committee's proposal, the Meeting
resolved that the Election Committee shall be composed of representatives for
the three largest owners, as per the end of September, 2014, as well as the
Chairman of the Board.

The Meeting approved the Board's proposal concerning guidelines for
remuneration to the President and other senior executives. The guidelines
essentially conform to the principles applied to date.

In accordance with the Board's proposal, the Meeting resolved to authorize the
Board, for a period that does not extend past the date of the next Annual
General Meeting, to resolve on the issue of not more than seven million new
shares and/or convertibles with the corresponding dilution effect, with or
without pre-emptive rights for the company's shareholders.

Lund, May 16, 2014

Active Biotech AB (publ)

Tomas Leanderson
President and CEO

Active Biotech AB

ACTI) is a biotechnology company with focus on autoimmune/inflammatory
diseases and cancer.
Projects in pivotal phase are laquinimod (NERVENTRA®), an orally administered
small molecule with unique immunomodulatory properties for the treatment of
multiple sclerosis, tasquinimod for prostate cancer and ANYARA primarily for
the treatment of renal cell cancer.
In addition, clinical Phase II studies of laquinimod in Crohn's and Lupus have
been concluded.
The company also has one additional project in clinical development, the
orally administered compound paquinimod (57-57) for systemic sclerosis.
Please visit for more information.

Active Biotech is obligated to publish the information contained in this press
release in accordance with the Swedish Securities Market Act. This
information was provided to the media for publication
08:30 a.m. CET on May 16, 2014.

Active Biotech AB (Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 46 19 20 00
Fax: +46 46 19 11 00

Annual General Meeting of Active Biotech AB


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Active Biotech via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.